PO.CL01.02 · 临床研究
Biomarkers Predictive of Therapeutic Benefit 2
-
1033 · PDF Leronlimab 可诱导 PD-L1 表达,并与 PD-L1 低表达转移性 TNBC 患者接受 ICI 治疗后的长期生存相关 Leronlimab induces PD-L1 expression and is associated with long‑term survival with an ICI in PD-L1 low metastatic TNBC Richard G. Pestell, Ritika Harish, Zhiping Li, Danni Li, Xuanmao Jiao, Hallgeir Rui, Massimo Cristofanilli, Daniel L. Adams, Neil E. Buss, Jonah B. Sacha, Jacob P. Lalezari
-
1034 · PDF 与局部晚期/转移性(LA/M)头颈部鳞状细胞癌(HNSCC)患者对免疫治疗(IO)应答或耐药相关的转录组和基因组特征 Transcriptomic and genomic signatures associated with response or resistance to immunotherapy(IO) in locally advanced/metastatic (LA/M) head and neck squamous cell carcinoma (HNSCC) patients Elodie Girard, Sonia Canjura-Rodriguez, Bastien Cabarrou, Constance Lamy, Anne Schnitzler, Frédérique Penault-Llorca, Emmanuel Bouilhol, Roger Sun, Eric Deutsch, François Legrand, Séverine Tabone-Eglinger, Valery Attignon, Caroline Even, Christophe Le Tourneau, Ellen Van Obberghen-Schilling, Marta Jimenez, Nicolas Servant, Thomas Filleron, Edith Borcoman, Pierre Saintigny, Ivan Bièche
-
1035 · PDF 用于实体瘤早期治疗应答评估的超灵敏 cfDNA 片段组学检测 Ultrasensitive cfDNA fragmentomics assay for early treatment response assessment in solid tumors Atul Bharde, Kiran Kirdat, Amol Chaudhari, Ajay Pandita, Gowhar Shafi, Mohan Uttarwar, Sudhir K. Sinha, Hiromi Brown, Bill Haack
- 1036 1036 PPP2R1A 改变的整合临床病理学和基因组分析揭示子宫和卵巢癌中的不同模式 An integrated clinicopathologic and genomic analysis of PPP2R1A alterations reveals distinct patterns in uterine and ovarian cancers Kai Wang, Bo Yang, Chengyi Wang, Yannan Zhu, Jinmei Wang, Kunxu Xu, Zanmei Xu
- 1037 1037 接受免疫治疗(IO)的局部晚期/转移性头颈部鳞状细胞癌(LA/M SCCHN)患者临床结局的单细胞和空间分辨决定因素 Single cell and spatially resolved determinants of the clinical outcome of patients (pts) treated with locally advanced/metastatic head and neck squamous cell carcinoma (LA/M SCCHN) treated with immunotherapy (IO) Mehdi Lamkhioued, Thimothee Casini, Elodie Girard, Karène Mahtouk, Sonia Canjura-Rodriguez, Valery Attignon, Bastien Cabarrou, Constance Lamy, Anne Schnitzler, Frederique Penault-Llorca, Caroline Even, Christophe Le Tourneau, Ellen Van Obberghen-Schilling, Nicolas Servant, Fayette Jerome, Nathalie Bendriss-Vermare, Ivan Bièche, Pierre Saintigny
-
1038 · PDF 整合基因组学和真实世界数据以预测转移性乳腺癌不同 HER2 亚型对 fam-trastuzumab deruxtecan 的应答 Integrating genomics and real-world data to predict fam-trastuzumab deruxtecan response in metastatic breast cancer across HER2 subtypes Abraham Apfel, Alka A. Potdar, Yuanqing Ye, Viswanath Devanarayan, Evvie Jagoda, Shelley MacNeil, Yan Zhang, Pallavi Sachdev
-
1040 · PDF LiquidTME 的盲法临床验证——一种通过无创刻画肿瘤微环境来预测免疫治疗应答的无细胞 DNA 检测 Blinded clinical validation of LiquidTME, a cell-free DNA assay for predicting response to immunotherapy by noninvasively profiling the tumor microenvironment Aadel A. Chaudhuri, David Y. Chen, Tucker Hansen, Mirna Jarosz, Vincent A. Miller, Aaron M. Newman
-
1041 · PDF 细胞外囊泡相关的非经典 ORF 作为卵巢癌手术结局和化疗耐药的生物标志物 Extracellular vesicle-associated noncanonical ORFs as biomarkers of surgical outcome and chemoresistance in ovarian cancer Tatiana V. Karpinets, Xiaogang Wu, Sara Corvigno, Amma Asare, Joseph Celestino, Jeffry J. Cutrera, Pamela T. Soliman, Shannon N. Westin, Amir A. Jazaeri, P. Andrew Futreal, Anil K. Sood, Sanghoon Lee
-
1042 · PDF dMMR/MSI-H胃癌新辅助化学免疫治疗应答的临床与免疫相关因素 Clinical and immune correlates of response to neoadjuvant chemoimmunotherapy in dMMR/MSI-H gastric cancer Pengfei Yu, Xingmao Huang, Xiangliu Chen, Hang Chen, Song Wang, Di Wang, Junrong Yan, Jiahui Chen, Qing Wei, Zequan Wu, Shengxin Fang, Han Chen, Hongtao Wang, Chengkang Zhu, Ling Huang, Yian Du, Hua Bao, Haimeng Tang, Xue Wu, Xiangdong Cheng
-
1043 · PDF MUC5AC表达界定胰腺导管腺癌中一种免疫炎症型但功能受限的肿瘤微环境 MUC5AC expression defines an immune-inflamed but functionally restrained tumor microenvironment in pancreatic ductal adenocarcinoma Ashish Manne, Wancai Yang, Yongchen Guo, Vaibhav Sahai, Prachi Bajpai, Yonghua Bao, M Khalid Khan Niazi, Alejandro Leyva, Upender Manne
-
1044 · PDF II类HLA超型多样性预测泛癌队列中免疫检查点抑制剂治疗的不良结局 Class II HLA supertype diversity predicts poor outcomes with immune checkpoint inhibitors in a pan-cancer cohort Luke Xiyu Zhao, Franshisca Hayek, Howard Liu Li, Mark Yarchoan, Mari Nakazawa
-
1045 · PDF 一种新型上皮肿瘤特征谱预测非小细胞肺癌的生存及对PD-1阻断治疗的应答 A novel epithelial tumor signature predicts survival and response to PD-1 blockade in non-small cell lung cancer Muaath Alsufi, Jehad Yasin, Muthafar Alsufi, Osama Younis, Amro Assayed, Fawzi Abu Rous
-
1046 · PDF 利用转录组谱和深度学习通过softHRD检测乳腺癌中的同源重组缺陷 Leveraging transcriptomic profiles and deep learning to detect homologous recombination deficiency in breast cancer with softHRD Yashwin Madakamutil, Leo Joseph, Daniyal Rahman, Ammal Abbasi, Ludmil Alexandrov
-
1047 · PDF MORPHEUS-lung:转移性非小细胞肺癌患者接受atezolizumab+bevacizumab+立体定向体部放疗的生物标志物与临床应答 MORPHEUS-lung: Biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer Byoung Chul Cho, Sun Min Lim, Sang Hoon Lee, Dong Kwon Kim, Nuria Pardo, Hen Prizant, Yaacov R. Lawrence, Nedal Al-Sakaff, Hans-Joachim Helms, Gayevskiy Velimir, Barzin Nabet, Jan Pintoffl, Francois Ghiringhelli
-
1048 · PDF Smad缺陷通过改变胰腺腺癌的免疫-基质微环境影响化疗应答 Smad deficiency impacts chemotherapeutic responses through alterations in immuno-stromal microenvironment of pancreatic adenocarcinoma Chih Chieh Yen, Ying Jui Chao, Ping Jui Su, Ting Kai Liao, Wei Hsun Lu, Zhe Wei Hsu, Chien Jui Huang, I Ting Liu, Wen Yen Huang, Yan Shen Shan, Chia Jui Yen
-
1049 · PDF DNA修复表型可指导卡铂和PARP抑制剂的应答 DNA repair phenotypes inform carboplatin and PARP inhibitor response Ionut-Gabriel Funingana, John Ambrose, Luca Porcu, Philip Smith, Bradley Thomas, Ines Prata Machado, Patrick Tarpey, Mireia Crispin-Ortuzar, Marc Tischkowitz, Florian M. Markowetz, Alona Sosinsky, James D. Brenton
-
1050 · PDF 评估多重数字PCR中的光谱重叠与串扰,以有效监测癌症临床试验中的下一代CAR T细胞 Assessment of spectral overlap and crosstalk in multiplex digital PCR for effective monitoring of next-generation CAR T-cells in cancer clinical trials Sarah Johnson, Yogita Raj, Nathan Riccitelli
-
1051 · PDF CXCR4/LITAF作为伴肝转移胰腺癌尼妥珠单抗联合AG方案疗效的预测性生物标志物:整合单细胞与空间分析 CXCR4/LITAF as predictive biomarkers for nimotuzumab plus AG therapy in pancreatic cancer with liver metastasis: Integrative single-cell and spatial analysis Linze Xu, Yang Liu, Linlin Fu, Dandan Wu, Jin Zhang, Hao Wang, Huikai Li, Jihui Hao
-
1052 · PDF 真实世界治疗模式与结局揭示Cyclin E1阳性卵巢癌患者的独特临床轨迹 Real-world treatment patterns and outcomes reveal distinct clinical trajectories of patients with Cyclin E1-positive ovarian cancer Jinkil Jeong, Mona Abed, Catherine Lee, Heekyung Chung, Alexandra Levy, Nandini Molden, Divya Rajendran, Joyce F. Liu, Leslie M. Randall, Fiona Simpkins, Funda Meric-Bernstam, Danielle D. Jandial, Doris Kim, Olivier Harismendy
-
1053 · PDF 单细胞免疫分析揭示早期三阴性乳腺癌帕博利珠单抗疗效的生物标志物 Single-cell immune profiling reveals biomarkers of pembrolizumab response in early triple-negative breast cancer Inaki Comino-Mendez, Maria Rosario Chica-Parrado, María Elena Quirós-Ortega, Ana Godoy-Ortiz, Maria Emilia Dominguez-Recio, Esperanza López-López, María Victori Ortega-Jiménez, Martina Alvarez, Javier Pascual, Enrique de Alava, Emilio Alba
-
1054 · PDF 血浆代谢组学分析预测局部晚期NSCLC对新辅助免疫化疗的反应 Plasma metabolomic profiling predicts response to neoadjuvant immunochemotherapy in locally advanced NSCLC Yan Wang, Hui Yang Shi, Haonan Gu, Wenxin Jiang, Linyan Tian, Fang Wei, Danru Zheng, Haiyan Xu, Ting Xiao
-
1055 · PDF 评估用于胶质母细胞瘤患者反应分层的生物标志物可重复性 Assessing biomarker reproducibility for glioblastoma patient response stratification Christopher M. Jannotta, C. Zoe Linke, Charles A. Whittaker, Vikas Patil, Accelerating GBM Therapies TeamLab, Farshad Nassiri, Gelareh Zadeh, E. Antonio Chiocca, Alexander L. Ling
-
1056 · PDF III期NSCLC结局的整合多组学表征与AI驱动的生物标志物发现 Integrative multi-omics characterization and AI-driven biomarker discovery for NSCLC stage III outcomes Katherina C. Chua, Yun-Ching Chen, Ariel Chen, Stewart Bates, Mehdi Pirooznia, Assieh Saadatpour